Clinical Trial Detail

NCT ID NCT02122770
Title Effects of Fluconazole and Itraconazole CYP3A-Mediated Inhibition on the Pharmacokinetics, Safety, and Tolerability of MLN4924 in Patients With Advanced Solid Tumors
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Millennium Pharmaceuticals, Inc.
Indications

Advanced Solid Tumor

Therapies

Paclitaxel

Docetaxel

Itraconazole

Carboplatin

MLN4924

Fluconazole

Age Groups: adult

No variant requirements are available.